Immunome Inc. (IMNM)
Immunome Inc. (IMNM) from its SEC filings: 2025 revenue $6.9 million (-23% vs the year before), net margin -3060%, free cash flow -$200.6 million. Insider trades, recent filings and a price chart. Free.
| Exchange | Nasdaq |
| Industry | Pharmaceutical Preparations |
| Revenue (2025) | $6.9 million |
| Revenue growth | -23% |
| Net income | -$212.4 million |
| Net margin | -3060.0% |
| Free cash flow | -$200.6 million |
| Diluted EPS | $-2.43 |
| Latest quarter (Q2 2026 (calendar)) revenue vs a year earlier | -100% |
| Cash | $217.7 million |
| Long-term debt | $134,000 |
| Share count, 1 year | +30% |
| Fundamentals check | Weak fundamentals |
Source: SEC EDGAR company filings (XBRL), updated 2026-10-23. Education only, not financial advice.